Abstract：
The aim of the present study was to determine the associations between the MICB genetic variability and the expression and the risk of development of post-transplant complications after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT recipients and their donors were genotyped for two MICB polymorphisms (rs1065075, rs3828903). Moreover, the expression of a soluble form of MICB was determined in the recipients\' serum samples after transplantation using the Luminex assay. Our results revealed a favorable role of the MICB rs1065075 G allele. Recipients with donors carrying this genetic variant were less prone to developing chronic graft-versus-host disease (cGvHD) when compared to recipients without any symptoms of this disease (41.41% vs. 65.38%, p = 0.046). Moreover, the MICB rs1065075 G allele was associated with a lower incidence of cytomegalovirus (CMV) reactivation, both as a donor (p = 0.015) and as a recipient allele (p = 0.039). The MICB rs1065075 G variant was also found to be associated with decreased serum soluble MICB (sMICB) levels, whereas serum sMICB levels were significantly higher in recipients diagnosed with CMV infection (p = 0.0386) and cGvHD (p = 0.0008) compared to recipients without those complications. A protective role of the G allele was also observed for the rs3828903 polymorphism, as it was more frequently detected among donors of recipients without cGvHD (89.90% vs. 69.23%; p = 0.013). MICB genetic variants, as well as serum levels of sMICB, may serve as prognostic factors for the risk of developing cGvHD and CMV infection after allogeneic HSCT.
摘要：
本研究的目的是确定MICB遗传变异性与异基因造血干细胞移植（HSCT）后移植后并发症的表达和发展风险之间的关系。对HSCT接受者及其供体进行两种MICB多态性的基因分型(rs1065075,rs3828903)。此外，使用Luminex测定法在移植后的受者血清样本中测定MICB的可溶形式的表达。我们的结果揭示了MICBrs1065075G等位基因的有利作用。与没有任何这种疾病症状的接受者相比，携带这种遗传变异的捐赠者的接受者更不容易发生慢性移植物抗宿主病（cGvHD）（41.41％vs.65.38%,p=0.046)。此外，MICBrs1065075G等位基因与巨细胞病毒（CMV）再激活的发生率较低有关，作为供体（p=0.015）和受体等位基因（p=0.039）。还发现MICBrs1065075G变体与血清可溶性MICB（sMICB）水平降低有关，而与无这些并发症的受者相比,被诊断为CMV感染(p=0.0386)和cGvHD(p=0.0008)的受者血清sMICB水平显著较高.rs3828903多态性也观察到G等位基因的保护作用，因为它在没有cGvHD的接受者的捐赠者中更常见(89.90%vs.69.23%；p=0.013）。MICB遗传变异，以及血清sMICB水平，可能是同种异体HSCT后发生cGvHD和CMV感染风险的预后因素。
